Study of Individualized Amonafide to Treat Prostate Cancer

Phase 1/2 Completed 40 enrolled Xanthus Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).

Timeline

Start: 2004-03
Primary completion: 2005-12
Completion: 2005-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amonafide	Small molecule	—	Intravenous

Study of Individualized Amonafide to Treat Prostate Cancer

Summary

Timeline

Drugs

Indications